Experience the New World of NGS

Bring next-generation sequencing (NGS) into your own lab today

 

genexus-request-virtual-demo-cta

 

ThermoFisher NGS with Captions - Final H264

 

It's NGS as fast and easy as IHC or PCR

The Oncomine Precision Assay on the Ion Torrent Genexus System features a complete next-generation sequencing (NGS) testing workflow. Now every lab can go from specimen to report in a single day, providing a comprehensive genomic profile at a speed never possible before*.

This allows you to deliver NGS results at the same time as other single-gene methods, such as immunohistochemistry (IHC). The hands-off, set-up-and-go workflow makes NGS accessible, even if your lab is new to the technology.

With the lowest sample input requirement of any NGS solution, you can successfully sequence more precious samples—even when tissue is very limited.
 

 

Ion Torrent Genexus Systems

Introducing the first turnkey NGS system that automates the specimen-to-report workflow and delivers results in a single day. With just 10 minutes of hands-on time and two touch points, users can get up and running quickly with significantly less training. This highly flexible system lets you cost-effectively process samples as they come in - even just one.

Learn the benefits of the Genexus System.

Are you ready to experience the power of the Oncomine Precision Assay on the Genexus system?  Request a demonstration today and our representatives will contact you shortly.  

genexus-request-virtual-demo-cta

genexus-with-other-machines-V4FK2

Flexible Financing for Every Lab

Now you don’t have to wait to access the Genexus System. We are committed to supporting your
research by offering a wide range of financial and leasing programs for even easier adoption of NGS.

explore-financing-options-cta

 

Genexus Webinar Series

Enjoy this three-part on-demand series that gives you a closer look at the new Genexus System and FusionSync technology

Genexus News

Read the latest news about the Ion Torrent Genexus System.

read-genexus-news-cta

Animated Oncomine Specialist

opa-new

download-flyer-cta

 

Oncomine Precision Assay

The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes based on the latest therapy developments, medical guidelines, and clinical trials. Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from plasma or lysate derived from FFPE samples, giving you a wide range of utility. All of this is provided with a one-day turnaround time and a highly automated workflow on the Genexus System.

 

 

Don't Let Precious Samples Go Untested

Did you know that high sample input requirements significantly limit the usability of hybrid capture-based NGS tests? You might assume that all NGS tests are created equal. However, recent data from more than 20 US laboratories has shown that small biopsies and low-tumor content samples can pose significant challenges for some tests - some labs have test failure rates of 58%.

This means that less than half of all samples will be successfully sequenced. Not with Oncomine Solutions. You can experience a sequencing success rate of over 95% with only 10ng of nucleic acid input. Get NGS results for most of the precious samples you have.

less-sample-required

download-infographic-cta

 

Maximize your ability to detect key biomarkers

image_5dcd9adddca1f

Curated Pan-Cancer Content

  • Mutation, CNV and fusion variant types across 50 key genes
  • Driver and resistance variants
image_5dcd9af07c63b

FusionSync Detection

  • Sensitive and specific - targeted isoform designs
  • Novel fusion detection
molecular tagging

Molecular Tagging

  • Enhanced low-level variant detection
  • Key for liquid biopsy testing
image_5dcd9e228d989

Tissue and Plasma

  • One test, multiple sample types

FusionSyncTM Detection Technology

Gene fusions are an increasingly important target in precision oncology. Oncomine assays are superior for both sequencing success rate and sensitivity, two critical factors for fusion detection. Even when the tissue is very limited or the variants exist at low levels in the sample, you can detect key fusions by combining:

  • Targeted known fusion detection
  • Non-targeted detection of novel fusion combinations
  • Novel fusion detection

 

Fusion-Detection-Diagram

download-infographic-cta

 

 

Genexus Software - It's a New World

Are you worried about NGS bioinformatics? Using different software and requiring an expert to stich it all together? No need anymore! The Genexus Software, one secure, streamlined and easy-to-use NGS analysis software, provides a seamless experience from end to end, starting with entering sample data and finishing with report.

genexus-request-virtual-demo-cta

 

Oncomine Reporter

The Oncomine Reporter delivers clear and concise reports that present all relevant variants with annotated information about targeted therapies, guidelines, and enrollment of ongoing clinical trials.

The report is customizable so that you can tailor it to fit your team's needs.

Learn More About Oncomine Informatics

report-example-new

 

Watch this customer video to see easy NGS in action

A molecular biology laboratory at the Hospital Universitari Vall d'Hebron performs NGS analysis with the Genexus System.

NoInforme_NuevoTitulo (1)

 

 

Molecular Tagging

The Oncomine Precision Assay on the Ion Torrent Genexus System detects low-level variants that are particularly important for liquid biopsy testing. It provides:

  • Enhanced specificity
  • Enhanced sensitivity
  • Artifact detection

Screen Shot 2020-08-27 at 1.42.12 PM

Results from Tissue and Plasma Samples

Although tissue samples are still the gold standard for molecular profiling, there exist many limitations.

Tissue can be inaccessible or there may not be enough material to sequence. Further, obtaining a tissue sample is difficult to repeat and not useful for monitoring and the sample may not reflect tumor heterogeneity. Liquid biopsy may be a viable alternative to tissue sequencing, as it is minimally invasive, provides a comprehensive tumor profile, and allows for repeat sampling.

With the Oncomine Precision Assay, you have the flexibility to sequence standard tissue or minimally invasive plasma samples, from one test on a single workflow.

Screen Shot 2020-08-25 at 2.28.38 PM

Additional Resources

References:

1. Next-Generation Sequencing in 305 Consecutive Patents: Clinical Outcomes and Management Changes; Gregory J. Kubicek, MD., et al., Journal of Clinical Oncology, Aug. 2019.
2. J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
3. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer; Jason Zhu, et al.; Urologic Cancer: Seminars and Original Investigations, July 2019.
4. Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine™ TML and FoundationOne™ assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Heeke S. et al. DOI: 10.1158/1538-7445.AM2019-4889; July 2019.

For Research Use Only.  Not for use in diagnostic procedures.  *Specimen-to-report workflow will be available after the Ion Torrent Genexus Purification System and integrated reporting capabilities are added in 2021 with the Genexus 6.4 software upgrade.